scholarly journals THE COMPLEMENT C1Q TUMOUR NECROSIS FACTOR-RELATED PROTEIN 1 LEVEL IN PATIENTS WITH SLEEP APNOEA AND PRIMARY ALDOSTERONISM

Heart ◽  
2012 ◽  
Vol 98 (Suppl 2) ◽  
pp. E102.1-E102
Author(s):  
Yao Xiao-guang ◽  
Cheng Wei-ping ◽  
Ma Wan-yong ◽  
Yan Zhi-tao ◽  
Bi Yun-wei ◽  
...  
2014 ◽  
Vol 129 (1) ◽  
pp. 73-78 ◽  
Author(s):  
H Jiang ◽  
H Cao ◽  
P Wang ◽  
W Liu ◽  
F Cao ◽  
...  

AbstractObjective:To explore the significance of the tumour necrosis factor-α/interleukin-10 ratio and the effect of continuous positive airway pressure in patients with different degrees of obstructive sleep apnoea hypopnoea syndrome severity.Method:This study comprised 135 patients with obstructive sleep apnoea hypopnoea syndrome and 94 control subjects.Results:Tumour necrosis factor-α and tumour necrosis factor-α/interleukin-10 ratio values were significantly higher in the obstructive sleep apnoea hypopnoea syndrome group than in the control group, but interleukin-10 was significantly lower. Tumour necrosis factor-α/interleukin-10 ratio values increased in line with the severity of obstructive sleep apnoea hypopnoea syndrome. In multivariate analysis, the tumour necrosis factor-α/interleukin-10 ratio correlated positively with the apnoea–hypopnoea index and all indices of obstructive sleep apnoea hypopnoea syndrome, except for age, body mass index and neck circumference. After one month of continuous positive airway pressure therapy, levels of tumour necrosis factor-α decreased; interleukin-10 showed no change.Conclusion:The results suggest that inflammation is activated and anti-inflammatory cytokines are decreased in obstructive sleep apnoea hypopnoea syndrome patients. Tumour necrosis factor-α/interleukin-10 ratio may prove useful for severity monitoring and management of obstructive sleep apnoea hypopnoea syndrome patients, and may reduce the need for polysomnography.


2018 ◽  
Vol 12 (3) ◽  
pp. 420-426 ◽  
Author(s):  
Diego Barbieri ◽  
Marian Goicoechea ◽  
Maria Dolores Sánchez-Niño ◽  
Alberto Ortiz ◽  
Eduardo Verde ◽  
...  

2015 ◽  
Vol 2015 ◽  
pp. 1-17 ◽  
Author(s):  
Simona Ronchetti ◽  
Erika Ricci ◽  
Maria Grazia Petrillo ◽  
Luigi Cari ◽  
Graziella Migliorati ◽  
...  

Glucocorticoid-induced tumour necrosis factor receptor-related protein (GITR, TNFRSF18, and CD357) is expressed at high levels in activated T cells and regulatory T cells (Tregs). In this review, we present data from mouse and human studies suggesting that GITR is a crucial player in the differentiation of thymic Tregs (tTregs), and expansion of both tTregs and peripheral Tregs (pTregs). The role of GITR in Treg expansion is confirmed by the association of GITR expression with markers of memory T cells. In this context, it is not surprising that GITR appears to be a marker of active Tregs, as suggested by the association of GITR expression with other markers of Treg activation or cytokines with suppressive activity (e.g., IL-10 and TGF-β), the presence of GITR+cells in tissues where Tregs are active (e.g., solid tumours), or functional studies on Tregs. Furthermore, some Treg subsets including Tr1 cells express either low or no classical Treg markers (e.g., FoxP3 and CD25) and do express GITR. Therefore, when evaluating changes in the number of Tregs in human diseases, GITR expression must be evaluated. Moreover, GITR should be considered as a marker for isolating Tregs.


Sign in / Sign up

Export Citation Format

Share Document